z-logo
Premium
Phellinus species: An emerging cause of refractory fungal infections in patients with X‐linked chronic granulomatous disease
Author(s) -
Haidar Ghady,
Zerbe Christa S.,
Cheng Michelle,
Zelazny Adrian M.,
Holland Steven M.,
Sheridan Kathleen R.
Publication year - 2017
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12573
Subject(s) - chronic granulomatous disease , mucormycosis , amphotericin b , aspergillosis , disease , refractory (planetary science) , mucorales , aspergillus , biology , medicine , immunology , antifungal , dermatology , pathology , microbiology and biotechnology , astrobiology
Summary Aspergillus spp. are a leading cause of mortality in chronic granulomatous disease ( CGD ), but other fungi have emerged in the era of mould prophylaxis. Of these, Phellinus spp. are an under‐recognised cause of invasive fungal infections ( IFI s) in CGD , and data on their presentation and management are scarce. We present a patient with CGD who developed disseminated IFI involving the lungs and brain. Surgical specimens grew a basidiomycete which was disregarded as a contaminant. After three months of progressive disease despite antifungals, he was diagnosed with Phellinus tropicalis by internal transcribed spacer ( ITS ) sequencing. He improved with amphotericin B and isavuconazole but required haematopoietic stem cell transplantation ( HSCT ). We review the literature on Phellinus infections in CGD and conclude that: (i) these infections emerge on mould‐active prophylaxis and are indolent; (ii) they typically cause locally destructive disease but can disseminate; (iii) diagnosis is delayed and requires molecular methods; (iv) amphotericin B is most active in vitro; and (v) treatment is protracted and requires surgery and possibly HSCT . In conclusion, Phellinus spp. are emerging pathogens in CGD . Every effort should be made to establish the diagnosis of non‐ Aspergillus IFI s in patients with CGD by sending tissue specimens for molecular diagnostics.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here